UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

NLRC5/MHC class I transactivator is a target for immune evasion in cancer

Proceedings of the National Academy of Sciences - PNAS, 2016-05, Vol.113 (21), p.5999-6004

2016

Volltextzugriff (PDF)

The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy

Frontiers in immunology, 2023-09, Vol.14, p.1237715

2023

Volltextzugriff (PDF)

Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy

Oncotarget, 2017-11, Vol.8 (57), p.96496-96505

2017

Volltextzugriff (PDF)

Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy

The cancer journal (Sudbury, Mass.), 2017-03, Vol.23 (2), p.144-148

2017

Volltextzugriff (PDF)

Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.787-801.e11

2024

Volltextzugriff (PDF)

Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease

Neuro-oncology (Charlottesville, Va.), 2023-08, Vol.25 (8), p.1415-1427

2023

Volltextzugriff (PDF)

808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A907-A907

2023

Volltextzugriff (PDF)

Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models

Vaccine, 2007-11, Vol.25 (46), p.7955-7961

2007

Volltextzugriff (PDF)

Abstract 1705: Identification and validation of neoantigens for developing a preventive vaccine for mismatch-repair deficient cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1705-1705

2021

Volltextzugriff (PDF)

Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7), p.965-976

2024

Volltextzugriff (PDF)

Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches

Cancer discovery, 2021-05, Vol.11 (5), p.1024-1039

2021

Volltextzugriff (PDF)

Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner

Clinical cancer research, 2012-08, Vol.18 (16), p.4345-4355

2012

Volltextzugriff (PDF)

DINC 2.0: A New Protein-Peptide Docking Webserver Using an Incremental Approach

Cancer research (Chicago, Ill.), 2017-11, Vol.77 (21), p.e55-e57

2017

Volltextzugriff (PDF)

Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8 + T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma

Clinical cancer research, 2019-11, Vol.25 (21), p.6406-6416

2019

Volltextzugriff (PDF)

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines

Cancer research (Chicago, Ill.), 2012-10, Vol.72 (20), p.5209-5218

2012

Volltextzugriff (PDF)

IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells

International immunology, 2007-10, Vol.19 (10), p.1213-1221

2007

Volltextzugriff (PDF)

APE-Gen2.0: Expanding Rapid Class I Peptide–Major Histocompatibility Complex Modeling to Post-Translational Modifications and Noncanonical Peptide Geometries

Journal of chemical information and modeling, 2024-03, Vol.64 (5), p.1730-1750

2024

Volltextzugriff (PDF)

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

Cancer discovery, 2016-02, Vol.6 (2), p.202-216

2016

Volltextzugriff (PDF)

Vestigial-like 1 (VGLL1): An ancient co-transcriptional activator linking wing, placenta, and tumor development

Biochimica et biophysica acta. Reviews on cancer, 2023-05, Vol.1878 (3), p.188892-188892, Article 188892

2023

Volltextzugriff (PDF)

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

Clinical cancer research, 2013-03, Vol.19 (5), p.1225-1231

2013

Volltextzugriff (PDF)

Harnessing the Power of the Immune System to Target Cancer

Annual review of medicine, 2013-01, Vol.64 (1), p.71-90

2013

Volltextzugriff (PDF)

Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer

Cells (Basel, Switzerland), 2021-09, Vol.10 (9), p.2379

2021

Volltextzugriff (PDF)

1 – 25 von 111

Suche als RSS-Feed

Aktive Filter

KollektionNature Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(92)

Publikationsform

Sprache

Englisch
(111)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

NLRC5/MHC class I transactivator is a target for immune evasion in cancer

The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy

Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy

Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy

Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention

Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease

808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy

Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models

Abstract 1705: Identification and validation of neoantigens for developing a preventive vaccine for mismatch-repair deficient cancers

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity

Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches

Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner

DINC 2.0: A New Protein-Peptide Docking Webserver Using an Incremental Approach

Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8 + T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines

IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells

APE-Gen2.0: Expanding Rapid Class I Peptide–Major Histocompatibility Complex Modeling to Post-Translational Modifications and Noncanonical Peptide Geometries

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

Vestigial-like 1 (VGLL1): An ancient co-transcriptional activator linking wing, placenta, and tumor development

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

Harnessing the Power of the Immune System to Target Cancer

Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer

Aktive Filter

Suchergebnisse filtern